{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-25-010523","form_type":"8-K","ticker":"MXCT","cik":"0001287098","company_name":"MAXCYTE, INC.","filed_at":"2025-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.587288+00:00","generated_at":"2026-05-17T18:57:47.222352+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"MaxCyte Q2 revenue down 18% YoY; lowers 2025 core revenue guidance","bullets":["Total revenue $8.5M, down 18% YoY; core revenue up 8% to $8.2M.","Net loss $12.4M vs $9.4M loss in Q2 2024; operating expenses $21.2M.","Added two SPL clients in July (Adicet Bio, Anocca AB); total SPL agreements now 31.","Updated FY2025: core revenue flat to -10% YoY; SPL Program-related revenue ~$5M.","Expects year-end cash ≥ $155M; cites customer inventory, reprioritization headwinds."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-25-010523","json":"https://secwatch.observer/filing/0001558370-25-010523.json","markdown":"https://secwatch.observer/filing/0001558370-25-010523.md","text":"https://secwatch.observer/filing/0001558370-25-010523.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1287098/000155837025010523/0001558370-25-010523-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1287098/000155837025010523/mxct-20250806x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T18:57:47.222352+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}